What is the best strategy for investigating abnormal liver function tests in primary care? Implications from a prospective study

BMJ Open

Volumn 3, Issue 6, 2013, Pages

  Lilford, Richard J ^a   Bentham, Louise M ^a   Armstrong, Matthew J ^a   Neuberger, James ^b   Girling, Alan J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; PROTEIN;

ABDOMINAL RADIOGRAPHY; ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT DISEASE; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOBILIARY SYSTEM TUMOR; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; UNITED KINGDOM;

EID: 84879925255     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003099     Document Type: Article

References (20)

1. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-84.
2. Lilford RJ, Bentham L, Girling A, et al. Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. Health Technology Assessment, vol. 17. 2013, pp 1-307.
3. Sherwood P, Lyburn I, Brown S, et al. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001;322:276-8. (Pubitemid 32178555)
4. World Health Organisation. Geneva: Good clinical laboratory practice (GCLP). World Health Organization on behalf of the special programme for research and training in tropical diseases. Geneva: World Health Organisation Press, 2009.
5. StataCorp. Stata statistical software: release 12. College Station, TX: StataCorp LP, 2011.
6. Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess 2009;13:1-156.
7. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9. (Pubitemid 24359054)
8. McLernon DJ, Dillon JF, Sullivan FM, et al. The utility of liver function tests for mortality prediction within one year in primary care using the Algorithm for Liver Function Investigations (ALFI). PLoS ONE 2012;7:e50965.
9. Health Protection Agency. Hepatitis C Information. Health Protection Agency, 2003. http://www.hpa.org.uk/infections/topics-az/hepatitis-c/phlsgen- info.htm (accessed 25 Mar 2013).
10. Health Protection Agency. Hepatitis B information. Health Protection Agency, 2003. http://www.hpa.org.uk/infections/topics-az/hepatitis-b/gen-info. htm (accessed 25 Mar 2013).
11. Worwood M. Haemochromatosis. Clin Lab Haematol 1998;20:65-75.
12. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24. (Pubitemid 29407371)
13. Arnold DT, Bentham LM, Jacob RP, et al. Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort? BMC Fam Pract 2011;12:9.
14. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large, prospective primary care cohort. J Hepatol 2012;56:234-40.
15. Muijtjens AM, Van Luijk SJ, Van Der Vleuten CP. ROC and loss function analysis in sequential testing. Adv Health Sci Educ Theory Pract 2006;11:5-17. (Pubitemid 43494597)
16. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71. (Pubitemid 30235957)
17. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005;172:367-9.
18. Theal RM, Scott K. Evaluating asymptomatic patients with abnormal liver function test results. Am Fam Physician 1996;53:2111-19. (Pubitemid 26135738)
19. De Bono M, Fawdry RD, Lilford RJ. Size of trials for evaluation of antenatal tests of fetal wellbeing in high risk pregnancy. J Perinat Med 1990;18:77-87. (Pubitemid 20162872)
20. di Ruffano L Ferrante, Hyde CJ, McCaffery KJ, et al. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012;344:e686.